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We describe the complete genome sequence of Burkholderia pseudomalleiMSHR305, a clinical isolate taken from a fatal enceph-
alomyelitis case, a rare form of melioidosis. This sequence will be used for comparisons to identify the genes that are involved in
neurological cases.
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Burkholderia pseudomallei is a Gram-negative saprophytic bac-terium endemic to southeast Asia and northern Australia (1).
It is the etiological agent of melioidosis, a disease that can present
in numerous forms, from cutaneous to pneumonia to septicemia
(2). Neurological cases occur rarely, in only 3 to 4% of patients,
and in murine models, inhalation led to direct brain infection,
presumably through the nasal mucosa via the olfactory nerve (2–
4). B. pseudomallei strain MSHR305 was isolated in 1994 during
an autopsy of a fatal melioidosis encephalomyelitis case at the
Royal Darwin Hospital, Northern Territory, Australia, and was
previously sequenced to 36 contigs (5).
DNA sequencing was performed by the Los Alamos National
Laboratory (LANL) Genome Science Group using Illumina and
PacBio technologies (6, 7). Short-insert paired-end Illumina li-
braries yielded 27,714,112 reads totaling 27.7 Mbp, and long-
insert libraries generated 920,819 paired reads totaling 159 Mbp.
The PacBio library generated 260,870 subreads for a total of
570 Mbp. The Illumina short-insert and long-insert paired data
were assembled together using Newbler version 2.6. The Newbler
consensus sequences were computationally shredded into 2-kbp
overlapping short reads (shreds). The Illumina data were also as-
sembled with Velvet version 1.2.08 (8), and the consensus se-
quence was shredded into 1.5-kbp overlapping shards. The draft
data from all platforms were assembled together with AllPaths,
version 39750, and the consensus sequence was shredded into
10-kbp overlapping shreds. We integrated consensus shreds from
Newbler, Velvet, and AllPaths along with a subset of read pairs
from the Illumina long-insert library using parallel Phrap version
SPS-4.24 (High Performance Software, LLC). Gap closure was
accomplished using PacBio consensus sequences.
The final assembly consisted of two chromosomes of lengths
4,054,138 and 3,373,904 bp, with average coverages of 287! and
79.2! for the Illumina and PacBio reads, respectively, and 6,209
total predicted genes. A comparison to the prototypic strain
B. pseudomallei K96243 and to B. pseudomalleiMSHR668, an iso-
late from a nonfatal encephalomyelitis case (5), revealed the pres-
ence of a hemolysin and activator protein on chromosome 1 in
MSHR305 andMSHR668 that is not present in K96243.However,
BLAST searches reveal that these proteins are in most B. pseu-
domallei strains.With the results of Owen et al. (4), it appears that
most strains have the capacity to cause neurological melioidosis if
the bacteria are inhaled and travel directly to the brain. We note
thatMSHR305 is one of the six priorityB. pseudomallei strains that
were selected as challenge materials for medical countermeasure
(MCM) efficacy testing by the Biomedical AdvancedResearch and
Development Authority (BARDA) (9).
Nucleotide sequence accessionnumbers.Thiswhole-genome
sequencing project has been deposited at GenBank under the ac-
cession no. CP006469 and CP006470. The version described in
this paper is the first version.
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